Controlling and eliminating neglected diseases in Latin America and the Caribbean

Health Affairs

Volumn 28, Issue 6, 2009, Pages 1707-1719

  Bitran, Ricardo ^a   Martorell, Bernardo ^a   Escobar, Llllana ^a   Munoz, Rodrigo ^a   Glassman, Amanda ^b,c  

^a Bitran and Associates   (Chile)

^b INTER AMERICAN DEVELOPMENT BANK   (United States)

^c BROOKINGS INSTITUTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HELMINTHIASIS; HOOKWORM INFECTION; INFECTION CONTROL; LYMPHATIC FILARIASIS; NONHUMAN; ONCHOCERCIASIS; PREVALENCE; SOUTH AND CENTRAL AMERICA; TRACHOMA; TROPICAL DISEASE;

CARIBBEAN REGION; COMMUNICABLE DISEASE CONTROL; HEALTH CARE COSTS; HUMANS; LATIN AMERICA; NEGLECTED DISEASES; ONCHOCERCIASIS; TRACHOMA; TROPICAL MEDICINE;

EID: 77952130943     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.6.1707     Document Type: Conference Paper

References (30)

1. Global Network for Neglected Tropical Diseases [Internet]. Washington: Sabin Institute; c2009. Press release. New analysis finds that neglected tropical disease burden in Latin America and Caribbean may exceed that of HMAIDS, TB, and malaria; 2008 Sep 24 [cited 2009 Sep 30]. Available from: http://www.prwebdirect.com/releases/2008/9/prweb1377304.htm
2. Lammie PJ, Lindo JF, Secor WE, Vasquez J, Ault SK, Eberhard ML Eliminating lymphatic filariasis, onchocerciasis, and schistosomiasis from the Americas: breaking a historical legacy of slavery. PLoS Negl Trop Dis. 2007;1(2):e71.
3. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008;2(9):e300.
4. Estimates of the total target populations for these diseases, including people at risk but not infected are available in an Annex, online at http://content.healthaffairs.org/cgi/content/full/28/6/1707/DCl.
5. World Health Organization. Global burden of disease study 2005. Geneva (Switzerland): WHO; 2005 [cited 2009 Oct 5]. Available from http://www.who.int/ healthinfo/global-burden-disease/GBD-2005-study/en/index.html
6. Molyneux D. Lymphatic filariasis (elephantiasis) elimination: a public health success and devdopment opportunity. Filaria J. 2003;2(13). Available from http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=200964&blobtype-pdf
7. Cattaneo MD, Galiani S, Gertler PJ, Martinez S, Titiunik R. Housing, health, and happiness [Internet]. La Plata (Argentina): Centra de Estudios Distributivos, Laborales y Sociales; 2008 Jul 12 [cited 2009 Oct 5]. World Bank Policy Research Working Paper no. 4214. Available from http://papers.ssrn.com/ sol3/papers.cfm?abstract-id=981822
8. Migud E, Kroner M. Worms: identifying impacts on education and health in the presence of treatment externalities. Econometrica. 2004;72(1):159-217.
9. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans D, et aL, editors. Disease control priorities in devdoping countries. 2nd ed New York (NY): Oxford University Press for the World Bank; 2006.
10. Molyneux D. Lymphatic filariasis (elephantiasis) elimination: a public health success and devdopment opportunity. Filaria J. 2003;2(13).
11. Perera M, Whitehead M, Molyneux D, Weerasooriya M, Gunatilleke G. Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis. PLoS. 2007;1(2):e128.
12. Chan MS, Bundy D. Epi Worm: a dynamic modd of intestinal helminth control Oxford (UK): Wellcome Trust Centre for the Epidemiology of Infectious Disease, Oxford University, 1999.
13. Anderson RM, May RM. Helminth infections of humans: mathematical models, population dynamics, and controL Adv in Parasitol. 1985;24:1-101.
14. Stolk WA, de Vlas SJ, Habbema JD. Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J. 2006;5:5.
15. Lee DC, Chidambaram JD, Porco TC, Lietman TM. Seasonal effects in the elimination of trachoma. Am J Trop Med Hyg. 2005;72(4):468-70.
16. Both models were implemented using Euler's method with a one-month step.
17. Chan MS, Bundy D. EpiSchisto: A dynamic modd of schistosomiasis controL Oxford (UK): Wellcome Trust Centre for the Epidemiology of Infectious Disease, Oxford University, 1999.
18. World Bank. School deworming at a glance. Washington (DC): World Bank; 2003.
19. Carabin H, Chan MS, Guyatt HL A population dynamic approach to evaluating the impact of school attendance on the unit cost and effectiveness of school-based schistosomiasis chemotherapy programmes. Parasitology. 2000;121(Pt 2):171-83.
20. Frick KD, Lietman TM, Holm SO, Jha HC, Chaudhary JS, Bhatta RC. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Organ. 2001;79(3):201-7.
21. Solomon AW Taylor HR. Trachoma: treatment and medication. eMedicine [Internet]. 2007 Sep 5 [cited 2009 Sep 30]. Available from http://emedicine. medscape.com/article/1202088-treatment
22. Kuper H, Solomon AW, Buchan J, Zondervan M, Foster A, Mabey D. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis. 2003;3(6):372-81.
23. Yorston D, Mabey D, Hatt S, Burton M. Interventions for trachoma trichiasis. Cochrane Database Syst Rev. 2006 Jul19;3:CD004008.
24. Burkot T, Durrheim D, Melrose WD, Speare R, Ichimori K. The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasis. Filaria J. 2006;5(10).
25. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, Garshong B, et aL National mass drug administration costs for lymphatic filariasis eliminatioa PLoS Negl Trop Dis. 2007;1(1):e67.
26. 2 = 77 percent).
27. Guyatt H. The cost of delivering and sustaining a control programme for schistosomiasis and soil-transmitted helminthiasis. Acta Trop. 2003;86(2-3):267-74.
28. Baltussen RM, SyHa M, Frick KD, Mariotti SP. Cost-effectiveness of trachoma control in seven world regions. Ophthalmic Epidemiol 2005;12(2):91-101.
29. The scale-up factor represents the annual rate at which mass drug administration is expanded in the target localities. For example, a scale-up factor of 20 percent means that 20 percent of the target localities will receive mass drug administration during the first year, 40 percent will be treated during the second and so on. A scale-up factor of 20 percent will require five years to achieve coverage in all target localities.
30. Inter-American Devdopment Bank [Internet]. Washington (DC): IDB; c2009. Press release, IDB, Global Network to mobilize $30 Million to fight neglected tropical diseases; 2009 Sep 23 [cited 2009 Sep 30]; [about 3 screens]. Available from http://www.iadb.org/news/detail.cfm?IJ?Language=English&rid= 5669